Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Choueiri, TK; Motzer, RJ; Rini, BI (Ann Oncol, 2020)
et al.